DRX 254

Drug Profile

DRX 254

Alternative Names: Deuterated CC 122; Deuterium stabilised CC 122; DRX-254

Latest Information Update: 10 Apr 2015

Price : $50

At a glance

  • Originator DeuteRx
  • Class Antineoplastics
  • Mechanism of Action Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Haematological malignancies; Solid tumours

Most Recent Events

  • 01 Apr 2015 Clinical trials in Haematological malignancies in USA (PO)
  • 01 Apr 2015 Clinical trials in Solid tumours in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top